Teva/Xenon’s Pain Ointment Failure Leaves Sparser Nav1.7 Pipeline
This article was originally published in The Pink Sheet Daily
Executive Summary
Once highly anticipated as an alternative mechanism for pain, the Nav1.7 target suffered another blow with Teva/Xenon’s failure of TV-45070 in osteoarthritis, though the class may still work in neuropathic pain.
You may also be interested in...
Genentech Bets On Kineta's Early-Stage, Disease-Modifying Pain Therapy
Genentech partners with the Seattle biotech on a non-opioid approach to chronic pain. Kineta says there's disease-modifying potential.
Genentech Seeks Partners For Biomarker-Driven Drug Development Beyond Oncology
Roche subsidiary hopes recent deals with 23andMe and Human Longevity for whole genome sequencing will help identify targets and biomarkers for Parkinson's disease and other non-cancer conditions. Firm also is taking a personalized medicine approach to development of treatments for pain, macular degeneration and asthma.
Xenon Feels No Pain After $41M Upfront From Teva
Teva and Xenon collaborate to develop the Canadian company’s lead pain product; the deal could net Xenon as much as $376 million and will fit snugly into the Israeli company’s new focus.